Paper Details

  1. Home
  2. Paper Details

A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS.

Author: HolodniyM, KhandwalaA, KochJ, MistalM, PenningtonJ E, PorterS B, SchmidtJ M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

SP-303 is safe and well tolerated in patients with AIDS and diarrhea, showing a potential for reducing stool weight and frequency.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: The aim of this study was to investigate the safety and effectiveness of orally administered SP-303 in patients with AIDS and diarrhea. METHODS: This is a multicenter, phase II, randomized, double blind, placebo-controlled study. HIV-positive subjects with a history of a CD4 count <200 o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1572-0241.1999.01535.x

データ提供：米国国立医学図書館（NLM）

SP-303: A Potential Oasis for Diarrhea in AIDS Patients

Diarrhea is a common and debilitating complication for patients with AIDS, making their lives feel like a never-ending desert trek. This study investigates the safety and efficacy of SP-303, a potential new treatment for diarrhea in AIDS patients.

SP-303: A Safe and Potentially Effective Treatment

The research shows that SP-303 is safe and well tolerated in AIDS patients with diarrhea. While the results suggest that SP-303 may be effective in reducing stool weight and frequency, further research is needed to confirm these findings. This study is like finding a promising oasis in the desert, offering a potential solution for a challenging problem.

Hope for Improved Management of Diarrhea

This research provides hope for improved management of diarrhea in AIDS patients, potentially leading to better quality of life for those affected.

Dr.Camel's Conclusion

The research on SP-303 is like discovering a promising oasis in the vast desert of AIDS complications. This potential new treatment offers a glimmer of hope for improving the lives of patients with diarrhea. Further exploration is needed to confirm its effectiveness and provide a true respite from this debilitating symptom.

Date :
  1. Date Completed 1999-11-30
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

10566728

DOI: Digital Object Identifier

10.1111/j.1572-0241.1999.01535.x

Related Literature

Article Analysis
・Side Effects of crofelemer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.